89bio, Inc.

NASDAQ:ETNB

8.47 (USD) • At close March 14, 2025
Bedrijfsnaam 89bio, Inc.
Symbool ETNB
Munteenheid USD
Prijs 8.47
Beurswaarde 1,236,484,480
Dividendpercentage 0%
52-weken bereik 5.986 - 13.71
Industrie Biotechnology
Sector Healthcare
CEO Mr. Rohan Palekar
Website https://www.89bio.com

An error occurred while fetching data.

Over 89bio, Inc.

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for

Vergelijkbare Aandelen

Unity Biotechnology, Inc. logo

Unity Biotechnology, Inc.

UBX

1.77 USD

Pulse Biosciences, Inc. logo

Pulse Biosciences, Inc.

PLSE

16.91 USD

Biodesix, Inc. logo

Biodesix, Inc.

BDSX

0.722 USD

Cryo-Cell International, Inc. logo

Cryo-Cell International, Inc.

CCEL

6.52 USD

Cardiff Oncology, Inc. logo

Cardiff Oncology, Inc.

CRDF

4 USD

Sensei Biotherapeutics, Inc. logo

Sensei Biotherapeutics, Inc.

SNSE

0.451 USD

Purple Biotech Ltd. logo

Purple Biotech Ltd.

PPBT

2.726 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)